Co-Diagnostics Inc. has formed a joint venture with Arabian Eagle Manufacturing—CoMira Diagnostics—to research, develop, manufacture, assemble, distribute, and commercialize Co-Dx technologies and intellectual property (IP), including the upcoming Co-Dx PCR point-of-care platform* within the Kingdom of Saudi Arabia and 18 other countries in the Middle East and North Africa.

CoMira’s mission aligns with the key pillars of Saudi Vision 2030, supporting technology localization, industrial diversification, and healthcare innovation, as the new venture engages in research, development, manufacturing, assembly, distribution, and commercialization of Co-Dx products.

“Arabian Eagle Manufacturing is proud to partner with Co-Diagnostics in establishing a transformative platform for molecular diagnostics within the Kingdom of Saudi Arabia,” Arabian Eagle CEO Ihssan Rjoob said. “This collaboration supports the goals of Saudi Arabia’s Vision 2030 by advancing health security, driving technology localization, and promoting sustainable industrial growth. This partnership represents a compelling model for combining international innovation with strong local leadership, utilizing machine learning and AI for continuous process improvement, and delivering lasting impact across healthcare and manufacturing ecosystems.”

The CoMira partners believe that initially pursuing regulatory clearance with the Saudi Food & Drug Administration (SFDA) will directly facilitate entry into many other Middle Eastern and North African countries.

Similar to the company’s partnership in India with CoSara Diagnostics Pvt. Ltd., Co-Dx will provide CoMira an exclusive license to use, manufacture, and commercialize the licensed IP, which will include the upcoming Co-Dx PCR platform as well as the company’s existing suite of lab-based PCR diagnostic products. Infectious disease tests on the new platform currently in preparation to begin clinical evaluations in various jurisdictions include tuberculosis, an eight-type HPV multiplex test, and an upper respiratory multiplex test for influenza A and B, COVID-19, and RSV.

“We are pleased to announce this agreement to establish the relationship with Arabian Eagle, our valued partners in the Middle East, as we expand the reach of our exciting healthcare innovations into a region with a large and growing market for medical devices and point-of-care diagnostics,” Co-Diagnostics CEO Dwight Egan commented. “The KSA has published the key demand drivers that underpin that anticipated growth, and we believe that our cutting-edge PCR technology, along with the scope and mission of CoMira, addresses those drivers while reinforcing our resolve to close the accessibility gap between high-quality PCR diagnostics and those who need them. Most importantly, we believe our shared mission to empower patients, clinicians, and healthcare providers with faster, more accessible and reliable diagnostic tools, will ultimately contribute to better health outcomes across the region.”

The principals of Arabian Eagle ran the primary distributor in the Middle East and were instrumental in KSA being one of the largest international markets for Co-Diagnostics’ Logix Smart tests. According to the joint venture agreement, Arabian Eagle will contribute local operational and customer support, lead the manufacturing facility set-up and regulatory clearance/registration responsibilities, manage other logistics activities, and ensure compliance with local industrial and commercial laws in pursuit of the agreement’s objectives across the Territory.

Other MENA countries included in the Territory consist of Bahrain, Iraq, Jordan, Kuwait, Lebanon, Oman, Palestine, Qatar, Syria, Turkey, United Arab Emirates  (UAE), Yemen, Algeria, Egypt, Libya, Morocco, Sudan, and Tunisia.

*The Co-Dx PCR platform (including the PCR Home, PCR Pro, mobile app, and all associated tests) is subject to review by the U.S. Food and Drug Administration and/or other regulatory bodies and is not currently available for sale.

Utah-based Co-Diagnostics Inc. is a molecular diagnostics company that develops, manufactures, and markets state-of-the-art diagnostics technologies. The company’s solutions are used for tests that detect and/or analyze nucleic acid molecules (DNA or RNA). The company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease.

Arabian Eagle Manufacturing is a Saudi-based investment and operating company focused on building high-impact industrial and healthcare ventures across the Kingdom. The company integrates artificial intelligence and automation technologies to accelerate growth, efficiency, and innovation across its projects. Arabian Eagle Manufacturing’s mission aligns with the objectives of Saudi Vision 2030, with a firm commitment to strengthening national capabilities, supporting healthcare providers with cutting-edge technologies, and enhancing the quality of care available to patients. Through regional expertise, regulatory insight, and global collaboration, the company aims to position Saudi Arabia as a leader in sustainable healthcare innovation.